Toray, JT, Torii to Co-Develop, Market TRK-820 Antipruritus Drug for Hepatic Disease Patients in Japan.Tokyo, Japan, Sept 5, 2006 - (JCN) - Toray, Japan Tobacco and Torii Pharmaceutical have agreed to develop and market TRK-820, an antipruritic antipruritic /an·ti·pru·rit·ic/ (-proo-rit´ik) preventing or relieving itching, or an agent that does this. an·ti·pru·rit·ic adj. Preventing or relieving itching. agent discovered at Toray's Pharmaceutical Research Laboratories, for hepatic disease patients in Japan. The companies are already engeged in development of the agent as a treatment for uremic uremic pertaining to or emanating from uremia. uremic poisoning see uremia, visceral gout. uremic toxins pruritus pruritus /pru·ri·tus/ (proo-ri´tus) itching.prurit´ic pruritus a´ni intense chronic itching in the anal region. pruritus hiema´lis xerotic eczema. in hemodialysis patients. Hepatic disease-related pruritus is a non-inflammatory systemic or local severe itching condition with an unclear pathology, which leads to sleep disturbances with patients with serious itching conditions. To date, conventional antipruritic agents have not proven fully effective in treating this condition. TRK-820 is a selective kappa opioid receptor The κ-Opioid receptors are a class of opioid receptors with dynorphins as the primary endogenous ligands, and ketazocine as a potent selective exogenous ligand. There are three variants: κ1, κ2, and κ3. agonist with a novel mechanism of action which differs from that for conventional drugs such as antihistamine antihistamine (ăn'tĭhĭs`təmēn), any one of a group of compounds having various chemical structures and characterized by the ability to antagonize the effects of histamine. , and it is expected that the compound will be effective for treating itching that is resistant to existing therapeutics. In the agreement announced September 5, Toray and JT will co-develop the agent, while Torii will carry out marketing in the area of hepatic disease-related pruritus as well as uremic pruritus in hemodialysis. On-going clinical development of TRK-820 for uremic pruritus in hemodialysis patients by collaboration of these three companies is in the final stage of the study. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion